| Literature DB >> 34345433 |
Alicia Murdoch1, Karthik K Tennankore2,3, Clara Bohm4,5,6, Catherine M Clase7,8,9, Adeera Levin1,10, Hans Vorster1, Rita S Suri10,11,12.
Abstract
PURPOSE: The Canadian Nephrology Trials Network (CNTN) was formed in 2014 to support Canadian researchers in developing, designing, and conducting prospective studies in nephrology. In response to the changing landscape and needs within the Canadian nephrology research community, an interest in further growth and development of the network was identified. In the following report, we describe the process undertaken to re-envision the network through the creation of 3 new committees and how the committees are facilitating change and growth within the CNTN for future sustainability. SOURCES OF INFORMATION: To understand areas for improvement and capacity building, the organization charged with overseeing the CNTN, Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD), began by conducting an environmental scan. As well, 2 informal surveys were sent to nephrology professionals (who were members of the CNTN and the Canadian Society of Nephrology) and patient partners (from Can-SOLVE CKD).Entities:
Keywords: CNTN; clinical trials; committees; nephrology; patients
Year: 2021 PMID: 34345433 PMCID: PMC8283045 DOI: 10.1177/20543581211030396
Source DB: PubMed Journal: Can J Kidney Health Dis ISSN: 2054-3581
Figure 1.Workflow diagram showing the flow of information and the process used.
Figure 2.Core strengths of Canadian Nephrology Trials Network as reported by researcher respondents on a scale from 1 (not a strength) to 5 (very strong).
Figure 3.Main challenges for Canadian Nephrology Trials Network in overcoming barriers to randomized clinical trials as reported by researcher respondents, ranked from most to least challenging.
Support for Possible Expanded Services for CNTN as Reported by Researcher Respondents.
| Possible expanded CNTN services | Proportion of respondents support this option (41) |
|---|---|
| Registry of trials searchable by investigator and center | 71% (29) |
| National clinical trials coordinator who could assist local sites with start-up | 66% (27) |
| Registry of patients interested in clinical trials | 68% (28) |
| Training of coordinators to conduct trials | 46% (19) |
| Training of coordinators to recruit at nonuniversity sites | 46% (19) |
| Provide subsidies to community sites | 2% (1) |
| Independent data safety monitoring board for investigator-initiated clinical trials | 2% (1) |
Note. CNTN = Canadian Nephrology Trials Network.
Figure 4.Change in network structure preworkshop and postworkshop.
Comparison of Rigatto Publication Recommendations and Activities of CNTN Since September 2018.
| 2015 recommendation | Activities of CNTN since September 2018 |
|---|---|
| To promote a culture of collaboration rather than competition within the Canadian nephrology community | In-person (and virtual) meetings that take place during the Canadian Society of Nephrology (CSN) Annual General Meeting (AGM) and American Society of Nephrology (ASN) Kidney Week are important to the creation of a culture of collaboration |
| To promote ongoing discussion of clinical trial ideas to develop new studies | Biannual in-person meetings are important in the promotion of a collaborative culture and discussion of clinical trial ideas. The COVID-19 pandemic has hampered these efforts, but we have successfully hosted 2 virtual meetings and will continue these in the future as an accessible way for people to discuss trial ideas |
| To identify and address barriers to recruitment for ongoing studies | Trialists were invited to present on barriers to recruitment and how they might be overcome at symposium events. We hope to continue this in the future and will invite individuals to present to the network on issues in trial design and implementation |
| To hold regular face-to-face meetings to accomplish the first 3 goals | CNTN held 2 in person meetings before the COVID-19 pandemic restricted travel. The network will be re-instating these meetings once travel is allowed. At the 2019 meeting in Montreal, there were 37 attendees and at the 2019 meeting in Washington, DC, there were 26 attendees. During COVID-19, virtual events in November 2020 and April 2021, had 50 and 34 attendees, respectively |
| To develop a web-based system to connect investigators with interested centers across Canada | The website was upgraded to include a listing of investigator-initiated trials across Canada |
| To develop a central infrastructure of methodologists and coordinators to assist motivated investigators in the development and conduct of multicenter clinical trials | This type of infrastructure may not be something that CNTN can directly build at this time, but the capacity building committee is developing a hub-and-spoke model which will be able to help motivated investigators find the support they need |
| To promote, prioritize, and facilitate funding of nephrology randomized controlled trials through review and endorsement of protocols and create national and local advocacy for funding high-priority studies | Formal peer-review and endorsement of protocols continues to be a priority task for the CNTN. Through the upgrade of the website and creation of a quarterly newsletter, we are able to better promote studies and their findings |
Note. CNTN = Canadian Nephrology Trials Network.